Show simple item record

Files in this item


Item metadata

dc.contributor.authorTulloch, Fiona
dc.contributor.authorLuke, Garry A.
dc.contributor.authorRyan, Martin D.
dc.identifier.citationTulloch , F , Luke , G A & Ryan , M D 2018 , ' Problems in FMD eradication : a way forward? ' , Journal of Veterinary Medicine and Research , vol. 5 , no. 5 , 1140 . < >en
dc.identifier.otherPURE: 254465521
dc.identifier.otherPURE UUID: 6623abc5-d466-4052-82fb-20028836bd35
dc.identifier.otherORCID: /0000-0003-0859-2867/work/46569198
dc.descriptionThe authors would like to acknowledge the support of the Wellcome Trust (eGrantsref. No. 8048) and Biotechnology and Biological Sciences Research Council (BBSRC; Grants BB/K003801/1 and BB/L004526/1).en
dc.description.abstractFoot and Mouth Disease Virus (FMDV) is one of the most commonly reported OIE-listed pathogens. FMDV is one of the most contagious mammalian viruses known to man: the virus is endemic in many developing countries causing substantial economic loses and the restriction of international trade in animals/animal products. The virus infects domestic animals (cattle, pigs, sheep, goats), but also a wide range of wild-life species, the latter forming reservoirs of disease. The need to diagnose FMDV infections (serotype/strain identification) and vaccine production/testing requires expensive, high disease security/containment facilities. Chemically inactivated (‘killed’) vaccines have been available for decades, but the huge genetic diversity of this virus (7 serotypes with 1000s of subtypes) and the need to periodically re-vaccinate animals to maintain protective levels of antibodies argue for the development of new vaccines. Indeed, in the early 1990s, on the basis of a cost-benefit analysis, the European Union replaced the policy of routine vaccination using the inactivated vaccine with disease control via mass-slaughter of infected and surrounding susceptible animals (plus vaccination in extremis). For various reasons mass-slaughter is unacceptable in many developing countries so in their case vaccination, in one form or another, is the only way forward. In the past few years there have been exciting developments in the production of new types of vaccine and many hold great prospects for improving disease control, but the thesis of this paper is that only the development of a new type of vaccine – live, attenuated, FMDV strains, offers the prospect of eradicating FMDV.
dc.relation.ispartofJournal of Veterinary Medicine and Researchen
dc.rights© 2018 Ryan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en
dc.subjectFMDV disease controlen
dc.subjectFMDV eradicationen
dc.subjectInactivated FMDV vaccinesen
dc.subjectSub-unit FMDV vaccinesen
dc.subjectVirus-like particlesen
dc.subjectLive attentuated FMDV vaccinesen
dc.subjectQR355 Virologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleProblems in FMD eradication : a way forward?en
dc.typeJournal itemen
dc.contributor.sponsorThe Wellcome Trusten
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Biologyen
dc.contributor.institutionUniversity of St Andrews. Biomedical Sciences Research Complexen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record